Fluralaner

Fluralaner

200px
Names
IUPAC name 4-[(5R/S)-5-(3,5-Dichlorophenyl)-4,5-dihydro-5-trifluoromethyl-1,2-oxazol-3-yl]-N-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]-o-toluamide
Identifiers
CAS Number	864731-61-3 (A)
ChemSpider	29398949 Y
Jmol 3D model	Interactive image
InChI InChI=1S/C22H17Cl2F6N3O3/c1-11-4-12(2-3-16(11)19(35)31-9-18(34)32-10-21(25,26)27)17-8-20(36-33-17,22(28,29)30)13-5-14(23)7-15(24)6-13/h2-7H,8-10H2,1H3,(H,31,35)(H,32,34) Y Key: MLBZKOGAMRTSKP-UHFFFAOYSA-N Y
SMILES Cc1cc(ccc1C(=O)NCC(=O)NCC(F)(F)F)C2=NOC(C2)(c3cc(cc(c3)Cl)Cl)C(F)(F)F
Properties
Chemical formula	C22H17Cl2F6N3O3
Molar mass	556.29 g·mol−1
Pharmacology
ATCvet code	QP53BE02
Vapor pressure	{{{value}}}
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references

Fluralaner is a systemic insecticide and acaricide that is administered orally. The US Food and Drug Administration (FDA) approved it under the trade name Bravecto for flea treatment in dogs in May 2014. The EU approved the drug in February 2014. Australia approved its use for sale as a flea and tick control treatment.

Mode of action

Fluralaner inhibits γ-aminobutyric acid (GABA)-gated chloride channels (GABACls) and l-glutamate-gated chloride channels (GluCls).